Two or four hour ( 18 F)FMISO-PET in HNSCC is the contrast best?
暂无分享,去创建一个
J. Steinbach | M. Baumann | D. Zips | N. Abolmaali | J. Kotzerke | K. Zöphel | R. Haase | A. Koch
[1] M. Baumann,et al. Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[2] F Hofheinz,et al. Effects of cold sphere walls in PET phantom measurements on the volume reproducing threshold , 2010, Physics in medicine and biology.
[3] John L. Humm,et al. Pharmacokinetic Analysis of Hypoxia 18F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer , 2010, Journal of Nuclear Medicine.
[4] Steen Jakobsen,et al. Can hypoxia-PET map hypoxic cell density heterogeneity accurately in an animal tumor model at a clinically obtainable image contrast? , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[5] Sigrid Stroobants,et al. Dose Painting in Radiotherapy for Head and Neck Squamous Cell Carcinoma: Value of Repeated Functional Imaging with 18F-FDG PET, 18F-Fluoromisonidazole PET, Diffusion-Weighted MRI, and Dynamic Contrast-Enhanced MRI , 2009, Journal of Nuclear Medicine.
[6] L. Dubois,et al. [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[7] M. Baumann,et al. Serial FDG-PET on patients with head and neck cancer: Implications for radiation therapy , 2009, International journal of radiation biology.
[8] W. Oyen,et al. Correlation of [18F]FMISO autoradiography and pimonodazole immunohistochemistry in human head and neck carcinoma xenografts , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[9] Sadek Nehmeh,et al. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography. , 2008, International journal of radiation oncology, biology, physics.
[10] Roland Bares,et al. Hypoxia-imaging with 18F-Misonidazole and PET: Changes of kinetics during radiotherapy of head-and-neck cancer , 2007 .
[11] Jörg van den Hoff,et al. Quantitative 3D ROI volume delineation in PET: Algorithm and validation , 2007 .
[12] M. Krause,et al. Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[13] M. Alber,et al. Imaging oxygenation of human tumours , 2006, European Radiology.
[14] Martin Westhofen,et al. FDG—a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[15] R. Fisher,et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Simon M. Ametamey,et al. NanoPET imaging of [18F]fluoromisonidazole uptake in experimental mouse tumours , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[17] Daniela Thorwarth,et al. Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer , 2005, BMC Cancer.
[18] Lester J. Peters,et al. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[19] Ming-fang Wang,et al. Fully automated one-pot synthesis of [18F]fluoromisonidazole. , 2005, Nuclear medicine and biology.
[20] Matthias Reimold,et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[21] Jean-François Daisne,et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. , 2004, Radiology.
[22] J. Eary,et al. [18F]FMISO and [18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[23] M. Dewhirst,et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.
[24] T K Lewellen,et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.
[25] A. Nunn,et al. Nitroimidazoles and imaging hypoxia , 1995, European Journal of Nuclear Medicine.
[26] D. Hellwig,et al. Positron emission tomography 2008 in Germany , 2010, Nuklearmedizin.
[27] Gig Mageras,et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. , 2008, International journal of radiation oncology, biology, physics.
[28] R. Ewers,et al. Uptake of 18F-FLT and 18F-FDG in primary head and neck cancer correlates with survival , 2008, Nuklearmedizin.
[29] Sadek Nehmeh,et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. , 2008, International journal of radiation oncology, biology, physics.
[30] W. Oyen,et al. Correlation of [18F]FMISO autoradiography and pimonidazole immunohistochemistry in human head and neck carcinoma xenografts , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[31] Kenneth A Krohn,et al. Imaging hypoxia and angiogenesis in tumors. , 2005, Radiologic clinics of North America.
[32] L. Adler,et al. PET imaging in soft tissue sarcomas. , 1997, Cancer treatment and research.
[33] P Vaupel,et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[34] K. Krohn,et al. Synthesis and characterization of congeners of misonidazole for imaging hypoxia. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.